...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
【24h】

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

机译：选择性5-羟色胺再摄取抑制剂的增加可治疗精神分裂症的阴性症状。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

SUMMARY: The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Important methodological issues such as differentiating primary and secondary negative symptoms are discussed. The balance of available evidence indicates that at least some SSRIs, fluvoxamine and fluoxetine, can ameliorate primary negative symptoms in chronic schizophrenia patients who are treated with typical antipsychotics. The combination is safe and well tolerated although, as antipsychotic drug concentrations may be elevated, attention to dose and drug monitoring should be considered as appropriate. The effect of SSRI augmentation of atypical antipsychotics requires further study. Combination with clozapine may require particular caution because of potential toxicity if serum clozapine levels rise steeply. SSRI augmentation may be a useful addition to the treatment of schizophrenia.
机译：摘要：精神分裂症的阴性症状的治疗提出了一项重大的临床挑战。这篇综述研究了在抗精神病药中添加选择性5-羟色胺再摄取抑制剂（SSRIs）治疗精神分裂症阴性症状的有效性，耐受性和安全性的证据。讨论了重要的方法论问题，例如区分主要和次要阴性症状。现有证据的平衡表明，至少一些SSRI（氟伏沙明和氟西汀）可以缓解接受典型抗精神病药治疗的慢性精神分裂症患者的主要不良症状。尽管由于抗精神病药的浓度可能会升高，所以这种组合是安全且耐受性良好的，因此应适当考虑注意剂量和药物监测。 SSRI增强非典型抗精神病药的作用需要进一步研究。与氯氮平合用可能需要特别注意，因为如果血清氯氮平水平急剧上升，可能会产生毒性。 SSRI增强可能是精神分裂症治疗的有用补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号